A 9-year-old neutered male Cavalier King Charles Spaniel ...

Thank you for providing such a detailed and thorough workup for this Cavalier King Charles Spaniel. Your precise observations allow for a clear assessment.

Based on the information you've provided, this patient is unequivocally in ACVIM Stage B2 Degenerative Mitral Valve Disease (DMVD).

Here's my reasoning and recommendation:

ACVIM Stage B2 Classification:

* The presence of a Grade IV/VI left apical systolic murmur confirms structural heart disease.
* The patient is currently asymptomatic, which rules out Stage C or D.
* Crucially, the echocardiogram demonstrates hemodynamically significant cardiac remodeling:
* An LA:Ao ratio of 2.0 is well above the normal threshold of <1.6 for dogs, indicating significant left atrial enlargement.
* An LVIDdN of 1.9 is also above the normal threshold of <1.7, indicating significant left ventricular dilation due to chronic volume overload.
* These findings together place the patient firmly in Stage B2, distinguishing it from Stage B1 where there is structural disease but no significant chamber enlargement.

When to Initiate Pimobendan:

Pimobendan should be initiated immediately for this patient.

Rationale for Initiation:

The recommendation for pimobendan at Stage B2 is strongly supported by the landmark EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly caused by preclinical mitral valve disease) trial. This large, prospective, randomized, blinded, placebo-controlled study demonstrated that initiating pimobendan in dogs with Stage B2 DMVD (defined by specific cardiomegaly criteria, similar to your patient's echo findings) significantly:
* Prolonged the pre-clinical period: It delayed the onset of clinical signs of congestive heart failure (CHF) by an average of 15 months.
* Extended overall survival: Dogs treated with pimobendan lived significantly longer.
The mechanism involves pimobendan's positive inotropic and vasodilatory effects, which improve cardiac output and reduce the work of the failing heart, thereby slowing the progression of remodeling and delaying CHF.

Pimobendan Dosing and Administration:

Per the verified drug formulary, the recommended dose for pimobendan in dogs is:
* Pimobendan: 0.25-0.3 mg/kg PO Every 12 hours.
It is critical to administer pimobendan on an empty stomach, ideally at least one hour before feeding, as food can significantly reduce its absorption by up to 30%.

Monitoring:

* Sleeping Respiratory Rate (SRR): This remains the single most important monitoring tool for owners at home. Instruct the owner to count the dog's breaths per minute while sleeping peacefully. A normal SRR is typically below 30 breaths/minute. An increase above this baseline, or a consistent trend upward, is often the earliest sign of impending CHF.
* Clinical Re-evaluation: I would recommend a recheck examination in 3-6 months, or sooner if any clinical signs develop.
* Echocardiography: A follow-up echocardiogram in 6-12 months can assess the progression of the disease and the effectiveness of therapy.

By starting pimobendan now, you are providing this patient with the best evidence-based opportunity to delay the onset of congestive heart failure and extend their quality of life. Please do not hesitate to reach out if you have any further questions or if the patient's condition changes.